Skip to main content

Peer Review reports

From: A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

Original Submission
26 Jan 2023 Submitted Original manuscript
27 Feb 2023 Reviewed Reviewer Report
1 Mar 2023 Reviewed Reviewer Report
4 Apr 2023 Author responded Author comments - Amirhossein Bahreyni
Resubmission - Version 2
4 Apr 2023 Submitted Manuscript version 2
14 Apr 2023 Reviewed Reviewer Report
17 Apr 2023 Reviewed Reviewer Report
25 Apr 2023 Author responded Author comments - Amirhossein Bahreyni
Resubmission - Version 3
25 Apr 2023 Submitted Manuscript version 3
4 May 2023 Author responded Author comments - Amirhossein Bahreyni
Resubmission - Version 4
4 May 2023 Submitted Manuscript version 4
10 May 2023 Author responded Author comments - Amirhossein Bahreyni
Resubmission - Version 5
10 May 2023 Submitted Manuscript version 5
Publishing
12 May 2023 Editorially accepted
24 May 2023 Article published 10.1186/s12916-023-02901-y

You can find further information about peer review here.

Back to article page